قسم الأدوية والسموم والطب الشرعي

المزيد ...

حول قسم الأدوية والسموم والطب الشرعي

حقائق حول قسم الأدوية والسموم والطب الشرعي

نفتخر بما نقدمه للمجتمع والعالم

20

المنشورات العلمية

7

هيئة التدريس

من يعمل بـقسم الأدوية والسموم والطب الشرعي

يوجد بـقسم الأدوية والسموم والطب الشرعي أكثر من 7 عضو هيئة تدريس

staff photo

أ.د. شعبان احمد خلف الله عويدات

shaban awidat هو احد اعضاء هيئة التدريس بقسم أدوية وسموم وطب شرعي بكلية الطب البيطري. يعمل السيد shaban بجامعة طرابلس كـأستاذ منذ 2017-03-15 وله العديد من المنشورات العلمية في مجال تخصصه

منشورات مختارة

بعض المنشورات التي تم نشرها في قسم الأدوية والسموم والطب الشرعي

Electorophysiological Study on the Interplay between Purinergic Nerves and Endothelial Cells in the Chicken Anterior Mesenteric Artery

Nerves and Endothelial Cells in the Chicken Anterior Mesenteric Artery arabic 16 English 118
Marwan Draid(1-2006)
Publisher's website

Effects of Anti-Tuberculous Drugs on Liver Function Profile in Libyan Patients with Tuberculosis

he present prospective study was designed to conduct a local survey on patients under anti-tuberculosis therapy hospitalized in Abo-Seta hospital, Tripoli, Libya from the safety point of view. The study was carried out on 75 inpatients. The effects of the used drugs on some hematological parameters and liver function biomarkers were monitored for six-month period of treatment. Our survey showed that tuberculosis affects people with low and medium levels of education and with no job. The frequency of adverse effects related to treatment with Abo-Seta hospital regimen were decreases in WBCs count (-38.7%), RBCs count (-32.1%), platelets count (-33%) and hemoglobin concentration (-35.5%). However, in most of the cases, it was not necessary to modify the treatment regimen because of such side effects. Some parameters showed spontaneous recovery as RBCs count (+22.1%) and hemoglobin level (+20.1%). Combined therapy of ethambutol, isoniazid, pyrazinamide, and rifampicin has been used in Abo-Seta hospital, as a regimen for tuberculosis infection, may be associated with a high risk of hepatic toxicity during first month of treatment. However, during the remaining five months there was a good recovery of liver enzymes profile. Upon the data obtained from the present study, it could be concluded that TB patient after 6 month of treatment didn't develop multi-drug resistant tuberculosis (MDR-TB arabic 13 English 83
Marwan Draid(7-2013)
Publisher's website

EFFECT OF SYNCHRONIZATION PROTOCOLS ON HAEMATOLOGICAL AND BIOCHEMICALPARAMETERS IN HEJAZI GOATS

ABSTRACT Background: The objective of this study was to evaluate changes of haematological and biochemical parameters in Hejazi goats under synchronization protocols treatment. Methods:Forty fertile and healthy female Hejazi goats were divided equally and randomly into four groups (n=10). All synchronization protocols started 7 days after the first 125 µg Cloprostenol injection (i.m.). The first group received CIDR treatment for 7 days only and followed by injection of second dose of PGF2α and 400 IU of PMSG, and the second group received CIDR treatment for 14 days and followed by injection of second dose of PGF2α and 400 IU of PMSG, and the third group received injection of 0.004 µg of synthetic GnRH analogue for 7 days and followed on day 14 by a second injection of 125 µg PGF2α followed by second injection of 0.004 µg of synthetic GnRH analogue, the fourth group received two doses of 125 µg PGF2α with14 days interval. Blood samples were collected from all of the does for biochemical analysis. Results: Observations showed no external or behaviour changes recorded and slight changes in all groups in diagnostic parameters. The conception rate tended to be decrease specific with increase in other days Conclusions: This study showed that monitoring the biochemical diagnostic parameters in the four groups going different protocols we didn’t record any significant different (P>0.05). The current study suggests that CIDR treatment for short and long are safe in Hejazi doe
Marwan M. Draid, Abdurraouf O. Gaja, Hoda R. Shnaishah(6-2021)
Publisher's website